The company has managed to raise USD 70 million, which it will use to progress its lead candidate into first-in-human clinical trials and broaden its pipeline of siRNA medicines.

Through this certified status, the CDMO will be able to offer its customers targeted, multiplex protein biomarker analysis alongside its human-relevant disease models.

Although the trial did not meet its primary endpoint, EyePoint reported a 42% reduction in overall treatment burden, with most patients requiring zero or one supplemental injection through Week 56.

The money from the oversubscribed Series C round will fund pivotal development of EPI‑321, a clinical-stage epigenetic therapy for FSHD, and supports late-stage development and expansion of manufacturing and pipeline programs.

The new partnership model combines Enzene’s continuous manufacturing platform with facility design, technology transfer, and operational support to help regions build cost-efficient biologics production capacity.

The first UK patient has been dosed in the Phase I NEOVACC trial using Touchlight’s proprietary doggybone DNA technology to manufacture a bespoke cancer vaccine.

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

The funding, which is part of a larger investment commitment from the European Commission, will be used to progress Ethris’ differentiated mRNA vaccine technology as a treatment for pandemic flu.

The nanoparticle suspension formulation was found to mirror the reference product closely in terms of AUC, Cmax, and Tmax across a 21-day Göttingen minipig study performed by Charles River Laboratories.

The company’s fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

The company has advanced its next‑generation tamper‑evident syringe closure from design finalization to industrialization ahead of a planned 2027 launch to strengthen its position in prefilled drug‑delivery solutions.

A new RSV A-strain challenge agent has been introduced by SGS to enhance CHIM studies and accelerate vaccine development. The breakthrough aims to generate more accurate, data-driven insights into RSV infection and immune response.

The companies will leverage GSK’s scientific expertise with LTZ’s immune engager platform to develop new first-in-class MCE therapies for the treatment of hematologic cancers and solid tumors.

Regeneron’s investigational gene therapy, DB-OTO, has been found to provide meaningful improvements in hearing for nearly all of the participants in the CHORD clinical trial.

Led by researchers at the University of Liverpool, a team of international scientists have discovered a new, potent class of antibiotics that will help in the fight against antimicrobial resistance.

At the 15th Drug Delivery & Formulation Summit in Boston, Nanoform unveiled proof‑of‑concept data demonstrating new approaches to biologic drug delivery.

In a financial report webcast, the Norwegian biotech presented breakthrough circVec-AAV data showing up to 40x higher protein expression than traditional mRNA-AAVs.

The grant money will be used by the biotechs to develop innovative targeted lipid nanoparticles that contain novel immune-silent DNA constructs for in vivo CAR T therapy.

The company’s research in a well-established rodent model has shown that EB-003 has potential as an effective treatment for post-traumatic stress disorder, representing an opportunity in an underserved market.

Business Finland is providing Nanoform with a EUR 5 million R&D loan to be used to accelerate the clinical development of the nanoformulated version of apalutamide through to the pivotal bioequivalence study.